Randomised phase 3 study of S-1 versus capecitabine, with bevacizumab optional in both arms, in the first-line treatment of metastatic colorectal cancer (mCRC), the SALTO study of the Dutch Colorectal Cancer Group

被引：1

作者：

Kwakman, J. J. M. ^{[1
]}

Simkens, L. H. J. ^{[2
]}

Van Rooijen, J. M. ^{[3
]}

de Wouw, A. J. Van ^{[4
]}

Loosveld, O. J. L. ^{[5
]}

Creemers, G. J. M. ^{[6
]}

Hendriks, M. P. ^{[7
]}

Los, M. ^{[8
]}

Van Alphen, R. J. ^{[9
]}

Polee, M. B. ^{[10
]}

Muller, E. W. ^{[11
]}

Van der Velden, A. M. T. ^{[12
]}

Van Voorthuizen, T. ^{[13
]}

Koopman, M. ^{[14
]}

Mol, L. ^{[15
]}

Van Werkhoven, E. ^{[16
]}

Punt, C. J. A. ^{[1
]}

机构：

[1] Acad Med Ctr, Med Oncol, Amsterdam, Netherlands

[2] Maxima Med Ctr, Med Oncol, Eindhoven, Netherlands

[3] Martini Hosp, Med Oncol, Groningen, Netherlands

[4] VieCuri Med Ctr, Med Oncol, Venlo, Netherlands

[5] Amphia Hosp, Med Oncol, Breda, Netherlands

[6] Catharina Hosp, Med Oncol, Eindhoven, Netherlands

[7] Med Ctr Alkmaar, Med Oncol, Alkmaar, Netherlands

[8] St Antonius Hosp, Med Oncol, Nieuwegein, Netherlands

[9] TweeSteden Hosp, Med Oncol, Tilburg, Netherlands

[10] Med Ctr Leeuwarden, Med Oncol, Leeuwarden, Netherlands

[11] Slingeland Hosp, Med Oncol, Doetinchem, Netherlands

[12] Tergooi Hosp, Med Oncol, Hilversum, Netherlands

[13] Rijnstate Hosp, Med Oncol, Arnhem, Netherlands

[14] Univ Med Ctr Utrecht, Med Oncol, Utrecht, Netherlands

[15] Netherlands Comprehens Canc Ctr, Dept Data Management, Nijmegen, Netherlands

[16] Netherlands Canc Inst, Dept Biometr, Amsterdam, Netherlands

来源：

EUROPEAN JOURNAL OF CANCER | 2017年 / 72卷

关键词：

D O I：

10.1016/S0959-8049(17)30099-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2BA

引用

页码：S5 / S5

页数：1

共 50 条

[21] A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
Tol, J.
Koopman, M.
Rodenburg, C. J.
Cats, A.
Creemers, G. J.
Schrama, J. G.
Erdkamp, F. L. G.
Vos, A. H.
Mol, L.
Antonini, N. F.
Punt, C. J. A.
ANNALS OF ONCOLOGY, 2008, 19 (04) : 734 - 738
[22] Phase I/II study of capecitabine(C)/oxaliplatin(O)/ irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Ou, K.
Liu, X.
Ma, X.
Gao, L.
Wang, Q.
Yang, L.
ANNALS OF ONCOLOGY, 2023, 34 : S1514 - S1514
[23] Phase II Study of Bevacizumab, Capecitabine, and Oxaliplatin Followed by Bevacizumab Plus Erlotinib as First-Line Therapy in Metastatic Colorectal Cancer
Munoz, Alberto
Pericay, Caries
Garcia-Giron, Carlos
Alonso, Vicente
Duenas, Rosario
Cirera, Luis
Rivera, Fernando
Falco, Esther
Alvarez Bustos, Inaki
Salud, Antonieta
ONCOLOGY RESEARCH, 2013, 21 (04) : 181 - 191
[24] PHASE II STUDY OF BEVACIZUMAB plus OXALIPLATIN PLUS CAPECITABINE FOLLOWED BY BEVACIZUMAB plus ERLOTINIB AS FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER
Munoz, A.
Pericay, C.
Llorente, B.
Alonso, V
Duenas, R.
Roca, J.
Rivera, F.
Falco, E.
Alvarez, I
Salud, A.
ANNALS OF ONCOLOGY, 2010, 21 : 73 - 74
[25] Updated results including quality of life of the phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG): Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC)
Punt, C. J. A.
Simkens, L. H. J.
May, A.
Mol, L.
Honkoop, A. H.
Rodenburg, C. J.
Zoon, P. J. C.
Schiphorst, P.
Van Tinteren, H.
Koopman, M.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S486 - S486
[26] UPDATED PHASE II STUDY RESULTS OF CAPECITABINE (X) plus IRINOTECAN (I) plus BEVACIZUMAB (A) AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)
Beslija, S.
Banjin, M.
Jungic, S.
Obralic, N.
Kecman-Malcic, G.
Rakita, I.
Salkic, B.
Pasic, A.
Tinjic, L.
ANNALS OF ONCOLOGY, 2008, 19 : 130 - 130
[27] Updated phase II study results of capecitabine (X) plus irinotecan (I) plus bevacizumab (A) as first-line therapy for metastatic colorectal cancer (MCRC)
Beslija, S.
Banjin, M.
Jungic, S.
Obralic, N.
Kecman-Malcic, G.
Rakita, I.
Salkic, B.
Pasic, A.
Tinjic, L.
Smoljanovic, V.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[28] UPDATED PHASE II STUDY RESULTS OF CAPECITABINE (X) plus IRINOTECAN (I) plus BEVACIZUMAB (A) AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)
Beslija, S.
Banjin, M.
Jungic, S.
Obralic, N.
Kecman-Malcic, G.
Rakita, I
Salkic, B.
Pasic, A.
Tinjic, L.
Smoljanovic, V
ANNALS OF ONCOLOGY, 2009, 20 : 76 - 76
[29] Capecitabine (X), irinotecan (I) and bevacizumab (A) as first-line therapy for patients (PTS) with metastatic colorectal cancer (MCRC): Preliminary phase II study results
Semir, Beslija
Maja, Banjin
Nadja, Paraganlija
Timur, Ceric
Anes, Pasic
Berisa, Salkic
Anes, Sosevic
Nermina, Obralic
ANNALS OF ONCOLOGY, 2006, 17 : 127 - 127
[30] Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
Tebbutt, Niall C.
Wilson, Kate
Gebski, Val J.
Cummins, Michelle M.
Zannino, Diana
van Hazel, Guy A.
Robinson, Bridget
Broad, Adam
Ganju, Vinod
Ackland, Stephen P.
Forgeson, Garry
Cunningham, David
Saunders, Mark P.
Stockler, Martin R.
Chua, YuJo
Zalcberg, John R.
Simes, R. John
Price, Timothy J.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) : 3191 - 3198

← 1 2 3 4 5 →